SC
EWTX icon

SummitTX Capital’s Edgewise Therapeutics EWTX Stock Holding History

SummitTX Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$599K Buy
+14,738
New +$508K 0.02% 559
2025
Q4 		– Sell
-20,782
Closed -$337K – 778
2025
Q3 		$337K Sell
20,782
-598
-3% -$8.48K 0.01% 607
2025
Q2 		$280K Buy
21,380
+11,716
+121% +$169K 0.01% 634
2025
Q1 		$213K Buy
+9,664
New +$254K 0.01% 724

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SummitTX Capital's EWTX Position: Q2 2026 in Review

SummitTX Capital opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 14,738 shares worth $599K. The stake represents 0.02% of the portfolio and ranks #559 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in EWTX as recently as Q3 2025.

SummitTX Capital first reported a position in EWTX in Q1 2025 and has held it in 4 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • SummitTX Capital held 14,738 shares of Edgewise Therapeutics worth $599K as of Q2 2026.
  • Edgewise Therapeutics was a new SummitTX Capital position in Q2 2026.
  • Edgewise Therapeutics made up 0.02% of SummitTX Capital's portfolio in Q2 2026, its #559 holding.
  • SummitTX Capital first reported a position in Edgewise Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.